Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Myelodysplastic Syndromes: Insights on Diagnosis, Risk Assessment, and Treatment Approaches for 2026

  • By

  • Guillermo Garcia-Manero

  • July 3, 2026

Share

  • 1

    MDS is a heterogeneous group of myeloid malignancies with a prevalence of 3 to 4 per 105 in the US, increasing with age.

  • 2

    Diagnosis of MDS is confirmed through bone marrow aspiration and biopsy, revealing dysplasia and cellular characteristics.

  • 3

    Risk assessment in MDS utilizes scoring systems like IPSS and IPSS-R, categorizing patients into lower and higher risk groups.

  • 4

    Cytogenetic analysis is crucial for prognosis and treatment decisions in MDS, with patterns evolving and impacting survival.

  • 5

    Diagnostic discrepancies in MDS can occur in 20% of patients, particularly in those with minimal dysplasia, affecting treatment.

Original Source(s)

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management

  • by Guillermo Garcia-Manero

  • July 3, 2026

Related Content

Erin Gillaspie, M.D. M.P.H., Joins Baptist Health Herbert Wertheim Cancer Institute as Chief of Thoracic Surgery

Erin Gillaspie, M.D., M.P.H., has joined Baptist Health Herbert Wertheim Cancer Institute and Baptist Health Cancer Care as chief of thoracic surgery.

  • by

  • November 3, 2026

  • 3 min
Increased Risk of Subsequent Cancers in Patients With Sézary Syndrome

Why Roswell Park for Hepatobiliary Cancer

Roswell Park Comprehensive Cancer Center performs more than 100 surgeries for patients with liver and pancreatic cancers every year, making it a high-volume center specializing in these rare diseases.

  • October 27, 2026

  • 2 min